CereXis

CereXis is a private U.S. clinical-stage biopharmaceutical company focused on targeted therapies for rare brain and nervous system cancers. Publicly available sources indicate the company's lead and apparently sole disclosed program is REC-2282, an oral small-molecule histone deacetylase inhibitor being developed for patients with Neurofibromatosis type 2-mutated meningiomas and related rare nervous system tumors. The company appears to have been formed as a Recursion spin-out centered on rare neuro-oncology. CereXis is based in New York and remains privately held, with no clear evidence of public-market listing or acquisition. Available information suggests a very lean organization with limited disclosed pipeline breadth beyond its lead asset.